Literature DB >> 9251728

Veno-occlusive disease of the liver in children treated for Wilms tumor.

G Bisogno1, J de Kraker, A Weirich, L Masiero, R Ludwig, M F Tournade, M Carli.   

Abstract

INTRODUCTION: Hepatotoxicity consistent with the clinical diagnosis of veno-occlusive disease (VOD) of the liver has been suspected after conventional anti-cancer chemotherapy in children.
METHODS: To establish the incidence of hepatotoxicity and its relationship with VOD, we analyzed toxicity data obtained on 511 children affected by Wilms tumor and treated according to the SIOP-9 protocol. They all received pre- and postnephrectomy chemotherapy using dactinomycin (AD) and vincristine (VCR) +/- other drugs +/- radiotherapy according to surgical stage and histology.
RESULTS: Sixty-four patients suffered at least one episode of hepatotoxicity and 41 satisfied the criteria for a clinical diagnosis of VOD. In this latter group, toxicity occurred during preoperative treatment in 15 patients and was confirmed histopathologically in 9 of the 16 liver biopsies obtained. There was a higher percentage of children aged less than 1 year at diagnosis in the VOD group than in the other patients (24% vs. 11.4%). The degree of liver damage in the younger patients seems important, as suggested by a higher increase in transaminases. VOD developed in 12% of the 68 irradiated children vs. 7% in the non-irradiated group. Statistical analysis showed an increased risk of VOD in younger patients (p < 0.001) and in those receiving radiotherapy (p < 0.001). All patients recovered after 6-180 days using supportive therapy only.
CONCLUSIONS: (1) 8% of children treated according to the SIOP-9 protocol, developed hepatotoxicity consistent with VOD. Excluding patients who received radiotherapy, the incidence was 6%. These figures are much higher than in earlier reports, though different diagnostic criteria were used. (2) Chemotherapy with AD and VCR seems to be a major cause of VOD. (3) Risk factors are young age and concomitant radiotherapy. (4) VOD does not prejudice positive outcome for these patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9251728     DOI: 10.1002/(sici)1096-911x(199710)29:4<245::aid-mpo2>3.0.co;2-m

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  15 in total

1.  Fatal hepatic sinusoidal obstruction syndrome in a child with primary CNS lymphoma during induction therapy.

Authors:  Shohei Yamamoto; Kousuke Akiyama; Nobuo Oyama; Mayumi Hayashi; Yoko Fujimoto; Hirokazu Ikeda; Keiichi Isoyama
Journal:  Int J Hematol       Date:  2012-06-27       Impact factor: 2.490

2.  Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.

Authors:  Conrad V Fernandez; Elizabeth J Perlman; Elizabeth A Mullen; Yueh-Yun Chi; Thomas E Hamilton; Kenneth W Gow; Fernando A Ferrer; Douglas C Barnhart; Peter F Ehrlich; Geetika Khanna; John A Kalapurakal; Tina Bocking; Vicky Huff; Jing Tian; James I Geller; Paul E Grundy; James R Anderson; Jeffrey S Dome; Robert C Shamberger
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

Review 3.  Hepatic veno-occlusive disease: a chemotherapy-related toxicity in children with malignancies.

Authors:  Maria Giuseppina Cefalo; Palma Maurizi; Annalisa Arlotta; Maria Scalzone; Giorgio Attinà; Antonio Ruggiero; Riccardo Riccardi
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

4.  Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.

Authors:  Christopher R Hill; Michael Cole; Julie Errington; Ghada Malik; Alan V Boddy; Gareth J Veal
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

5.  Hepatic Sinusoidal Obstruction Syndrome in a child after chemotherapy for medulloblastoma.

Authors:  M Kashif Ishaqi; A Jamil; M Khanani; M Baroudi; Omar Trad; M El-Hayek; Eric Bouffet
Journal:  J Neurooncol       Date:  2009-08-23       Impact factor: 4.130

6.  High Incidence of Veno-Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (CCG-99702).

Authors:  Kellie J Nazemi; Violet Shen; Jonathan L Finlay; James Boyett; Mehmet Kocak; Deborah Lafond; Sharon L Gardner; Roger J Packer; H Stacy Nicholson
Journal:  Pediatr Blood Cancer       Date:  2016-05-20       Impact factor: 3.167

7.  Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor for stage IV Wilms tumor: a report from the Children's Oncology Group/National Wilms Tumor Study Group.

Authors:  Peter F Ehrlich; Fernando A Ferrer; Michael L Ritchey; James R Anderson; Daniel M Green; Paul E Grundy; Jeffrey S Dome; John A Kalapurakal; Elizabeth J Perlman; Robert C Shamberger
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

8.  The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients.

Authors:  Hannah Yejin Kim; Gareth J Veal; Fanfan Zhou; Alan V Boddy
Journal:  Eur J Clin Pharmacol       Date:  2018-08-30       Impact factor: 2.953

9.  Dactinomycin-induced Hepatic Sinusoidal Obstruction Syndrome Responding to Treatment with N-acetylcysteine.

Authors:  Anselm Chi-Wai Lee; Peter Yu-Tang Goh
Journal:  J Cancer       Date:  2011-10-25       Impact factor: 4.207

10.  Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.

Authors:  Christopher R Hill; David Jamieson; Huw D Thomas; Colin D A Brown; Alan V Boddy; Gareth J Veal
Journal:  Biochem Pharmacol       Date:  2012-10-11       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.